2-(Bromomethyl)-4-chlorophenol | 117380-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(Bromomethyl)-4-chlorophenol
• 英文别名: 2-(bromomethyl)-4-chlorophenol
• CAS: 117380-00-4
• 化学式: C₇H₆BrClO
• 分子量: 221.48
• InChiKey: QTGQEAQYABZNPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• CATALYST FOR STEREOSELECTIVE OLEFIN POLYMERIZATION AND METHOD FOR MANUFACTURING STEREOSELECTIVE POLYOLEFIN
  申请人：Ishii Akihiko

  公开号：US20130059991A1

  公开（公告）日：2013-03-07

  A stereoselective olefin polymerization catalyst contains a complex represented by Formula (1): wherein n is 2 or 3; R 1 and R 2 are independently an optionally substituted alkyl group or a halogen atom; L is a ligand represented by CH 2 R 3 , a halogen atom, OR 4 , or NR 5 R 6 ; R 3 is a hydrogen atom, an aromatic group, or a trialkylsilyl group; R 4 is a lower alkyl group having 1 to 6 carbon atoms; and R 5 and R 6 are independently a hydrogen atom or a lower alkyl group having 1 to 6 carbon atoms. A method for manufacturing stereoselective polyolefin, includes polymerizing an olefin in the presence of the catalyst. The present invention provides a catalyst which enables highly isoselective polymerization generating a polymer having significantly high molecular weight and also can prepare stereoselective polyolefin with a narrow dispersity (Mw/Mn) or with a sharp molecular weight distribution, and provides a method for manufacturing stereoselective polyolefin with the catalyst.

  一种立体选择性烯烃聚合催化剂包含由式（1）表示的复合物： 其中n为2或3；R1和R2分别为可选择取代的烷基或卤素原子；L为CH2R3表示的配体、卤素原子、OR4或NR5R6；R3为氢原子、芳香族基团或三烷基硅基团；R4为具有1至6个碳原子的低烷基基团；R5和R6分别为氢原子或具有1至6个碳原子的低烷基基团。一种制备立体选择性聚烯烃的方法包括在催化剂存在下聚合烯烃。本发明提供了一种催化剂，可以实现高度立体选择性的聚合，生成具有显著高分子量的聚合物，并且可以制备具有窄分子量分布（Mw/Mn）或尖锐分子量分布的立体选择性聚烯烃，并提供了一种使用该催化剂制备立体选择性聚烯烃的方法。
• AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS
  申请人：AGV Discovery

  公开号：EP3170822A1

  公开（公告）日：2017-05-24

  The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the kinase ERK activity in particular ERK2 activity.

  本发明涉及一种化合物，其化学式为(I)，或其药学上可接受的盐之一，特别用作激酶ERK活性，特别是ERK2活性的抑制剂。
• Zaindole derivatives and their use as ERK kinase inhibitors
  申请人：AGV Discovery ENSCM

  公开号：US10995089B2

  公开（公告）日：2021-05-04

  The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.

  本发明涉及式 (I)：H或其药学上可接受的盐之一，特别是用作ERK激酶活性，尤其是ERK2活性的抑制剂，它还涉及这些化合物的原药。
• ETHYLENIC POLYMERIZATION CATALYST AND METHOD FOR MANUFACTURING ETHYLENIC POLYMER
  申请人：Ishi Akihiko

  公开号：US20130035462A1

  公开（公告）日：2013-02-07

  A catalyst for homopolymerization of ethylene or copolymerization of ethylene and an α-olefin comprises a complex represented by Formula (1): wherein n is 2 or 3; R 1 and R 2 are independently an optionally substituted alkyl group or a halogen atom; L is a ligand represented by CH 2 R 3 , a halogen atom, OR 4 , or NR 5 R 6 ; R 3 is a hydrogen atom, an aromatic group, or a trialkylsilyl group; R 4 is a lower alkyl group having 1 to 6 carbon atoms; and R 5 and R 6 are independently a hydrogen atom or a lower alkyl group having 1 to 6 carbon atoms. A method for manufacturing an ethylenic polymer involves homopolymerization of ethylene or copolymerization of ethylene and an α-olefin in the presence of the catalyst. The present invention provides a highly active tetradentate post-metallocene complex for ethylenic polymerization and a method for manufacturing the ethylenic polymer using the catalyst containing the complex.
• ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS
  申请人：AGV Discovery ENSCM

  公开号：US20200283432A1

  公开（公告）日：2020-09-10

  The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.